Vivesto Stock

Vivesto CROIC

The Cash Return on Invested Capital (CROIC) of Vivesto (VIVE.ST) as of Aug 16, 2026 is -35.09 %. In the previous year, Cash Return on Invested Capital (CROIC) was -24.22 % — a change of 44.87% (lower).

CROIC

-35.09 %

YoY

44.87%

Last updated:

Cash Return on Invested Capital (CROIC) of Vivesto is 2026 -35.09 % . Cash Return on Invested Capital (CROIC) of Vivesto was 2025 -24.22 % . It decreases by 44.87% lower compared to the previous year.
Access this data via the Eulerpool API

Vivesto Stock analysis

What does Vivesto do? Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden. Vivesto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vivesto stock

Cash Return on Invested Capital (CROIC) of Vivesto is -35.09 % in 2026.

Cash Return on Invested Capital (CROIC) of Vivesto changed from -24.22 % to -35.09 %, representing a 44.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Vivesto since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Vivesto with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — Vivesto

All Key Metrics — Vivesto